Inclusion Criteria:  Age ≥ 18 and ≤ 75 years old ; Patient with a moderate depressive episode (F32.1 by ICD10 definition) ; Score HAM-D ≥ 16 and ≤ 23 at inclusion, corresponding to moderate symptoms ; Recent depression (less than 6 months), not managed by antidepressant or psychotherapeutic treatment ; Depressive disorder not requiring, in the opinion of the investigator, initiation of antidepressant drug therapy ; Patient able to understand the study information, read the information leaflet, and willing to sign the consent form ; French speaking patient.  Exclusion Criteria:  Patient with a depressive disorder of another nature or any other mental illness (schizophrenia, bipolarity, alcohol or drug addiction, etc.); Patient at risk of suicide (noted by the investigator, or HAM-D item 3 score > 2) or having attempted suicide in the last 5 years; Depression felt for more than 6 months ; Patient under psychotropic treatment (current or in the month preceding inclusion) (neuroleptic, anxiolytic, hypnotic); Patient on beta-blocker therapy ; Patient on dialysis ; Patient using products containing piperine or St. John's wort, or having a known effect on mood in the last 30 days ; Woman who is pregnant or breastfeeding, or has plans to become pregnant in the next 8 weeks ; Patient with an allergy or contraindication to one of the components of the product under study (rhodiola or saffron) ; Patient unable to understand information related to the study (mental or linguistic disability) ; Patient participating or having participated in the previous 3 months in another clinical trial ;